Featured Tests


A complete testing portfolio powered by precision medicine.

OmniSeq Advance Assay


IntelliGEN® Myeloid

NGS assay covering 50 genes associated with myeloid malignancies

IntelliGEN® Myeloid


PIK3CA Mutation Analysis

FDA approved companion diagnostic for advanced breast cancer

PIK3CA Mutation Analysis


Resolution ctDx LungTM Assay

ctDNA liquid biopsy assay that targets actionable, somatic SNVs, indels, fusions, and copy number variants in 23 genes in NSCLC

Resolution ctDx Lung Assay

News & Announcements

FDA approved, companion diagnostic, QIAGEN therascreen® PIK3CA mutation analysis assay for breast cancer is now available

The assay is intended to aid clinicians in identifying PIK3CA-mutated advanced or metastatic breast cancer patients who may be eligible for treatment with PIQRAY® (alpelisib). [Press Release]

FDA approved, companion diagnostic, QIAGEN therascreen® FGFR mutation analysis assay for locally advanced or metastatic urothelial carcinoma, is now available

The assay is used to assess the eligibility of patients for treatment with the newly approved FGFR kinase inhibitor, BALVERSA (erdafitinib), developed by Janssen Biotech, Inc. (Janssen).  [Press Release]

NTRK Gene Fusions

TRK fusion proteins are oncogenic drivers that occur in a broad range of tumors across adult and pediatric cancers. Genomic profiling using either the OmniSeq AdvanceSM assay or the OmniSeq Comprehensive® assay can identify actionable NTRK gene fusions for TRK inhibitor treatment selection.

OmniSeq Advance Assay OmniSeq Comprehensive Assay